{"id":"https://openalex.org/W3029332117","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.6544","title":"INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.","display_name":"INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3029332117","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.6544","mag":"3029332117"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.6544","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.6544","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.6544","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028021994","display_name":"Erminia Massarelli","orcid":"https://orcid.org/0000-0001-7798-7286","observed_orcids":["https://orcid.org/0000-0001-7798-7286"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erminia Massarelli","raw_affiliation_strings":["City of Hope Helford Clinical Research Hospital, Duarte, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Helford Clinical Research Hospital, Duarte, CA;","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052730435","display_name":"Ani Sarkis Balmanoukian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]},{"id":"https://openalex.org/I4210104507","display_name":"Angeles Clinic and Research Institute","ror":"https://ror.org/01ct2ab72","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834","https://openalex.org/I4210104507"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ani Sarkis Balmanoukian","raw_affiliation_strings":["The Angeles Clinical & Research Institute, Cedars-Sinai Cancer, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Angeles Clinical & Research Institute, Cedars-Sinai Cancer, Los Angeles, CA;","institution_ids":["https://openalex.org/I1282927834","https://openalex.org/I4210104507"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004217317","display_name":"Mar\u00eda Vieito","orcid":"https://orcid.org/0000-0001-7531-343X","observed_orcids":["https://orcid.org/0000-0001-7531-343X"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Maria Vieito","raw_affiliation_strings":["Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain;","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063649167","display_name":"Christophe Le Tourneau","orcid":"https://orcid.org/0000-0001-9772-4686","observed_orcids":["https://orcid.org/0000-0001-9772-4686"]},"institutions":[{"id":"https://openalex.org/I80043","display_name":"Institut Curie","ror":"https://ror.org/04t0gwh46","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I80043"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christophe Le Tourneau","raw_affiliation_strings":["Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France;","institution_ids":["https://openalex.org/I80043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056008207","display_name":"Tatiana Hern\u00e1ndez\u2010Guerrero","orcid":"https://orcid.org/0000-0003-3459-871X","observed_orcids":["https://orcid.org/0000-0003-3459-871X"]},"institutions":[{"id":"https://openalex.org/I4210129357","display_name":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz","ror":"https://ror.org/049nvyb15","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210129357"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Tatiana Hernandez-Guerrero","raw_affiliation_strings":["START Madrid-FJD, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Madrid-FJD, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz, Madrid, Spain;","institution_ids":["https://openalex.org/I4210129357"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062111870","display_name":"Jos\u00e9 Manuel Trigo","orcid":"https://orcid.org/0000-0002-4489-2683","observed_orcids":["https://orcid.org/0000-0002-4489-2683"]},"institutions":[{"id":"https://openalex.org/I4210161852","display_name":"Hospital Universitario Ram\u00f3n y Cajal","ror":"https://ror.org/050eq1942","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210161852"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jose Manuel Trigo","raw_affiliation_strings":["Hospital Ram\u00f3n y Cajal, Madrid, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Ram\u00f3n y Cajal, Madrid, Spain;","institution_ids":["https://openalex.org/I4210161852"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110806811","display_name":"Raid M. Aljumaily","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039380","display_name":"OU Health Stephenson Cancer Center","ror":"https://ror.org/02bmcqd02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039271","https://openalex.org/I4390039380"]},{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raid Aljumaily","raw_affiliation_strings":["Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK;","institution_ids":["https://openalex.org/I4390039380","https://openalex.org/I49332381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038887077","display_name":"Michael Jon Chisamore","orcid":"https://orcid.org/0009-0006-8629-8232","observed_orcids":["https://orcid.org/0009-0006-8629-8232"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Jon Chisamore","raw_affiliation_strings":["Merck and Co., Kenilworth, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck and Co., Kenilworth, NJ;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053039666","display_name":"Debra Rogan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debra Rogan","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, Durham, NC;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084567986","display_name":"Ruby Sung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruby Sung","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033008162","display_name":"Courtney Henry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Courtney Henry","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022516918","display_name":"David C. Turner","orcid":"https://orcid.org/0000-0001-9242-6188","observed_orcids":["https://orcid.org/0000-0001-9242-6188"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Turner","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004072228","display_name":"Sapna Yadavilli","orcid":"https://orcid.org/0000-0001-6446-5032","observed_orcids":["https://orcid.org/0000-0001-6446-5032"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sapna Yadavilli","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102920475","display_name":"Sonia Franco","orcid":"https://orcid.org/0000-0001-9202-0022","observed_orcids":["https://orcid.org/0000-0001-9202-0022"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sonia Franco","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028688292","display_name":"Catherine Elizabeth Ellis","orcid":"https://orcid.org/0009-0008-7635-7846","observed_orcids":["https://orcid.org/0009-0008-7635-7846"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine Elizabeth Ellis","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088225387","display_name":"Marc S. Ballas","orcid":"https://orcid.org/0009-0001-3430-3742","observed_orcids":["https://orcid.org/0009-0001-3430-3742"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc S. Ballas","raw_affiliation_strings":["GlaxoSmithKline, Upper Providence, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Upper Providence, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086481435","display_name":"Axel Hoos","orcid":"https://orcid.org/0000-0001-5269-9376","observed_orcids":["https://orcid.org/0000-0001-5269-9376"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Axel Hoos","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA;","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060469120","display_name":"Danny Rischin","orcid":"https://orcid.org/0000-0002-3368-0386","observed_orcids":["https://orcid.org/0000-0002-3368-0386"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Danny Rischin","raw_affiliation_strings":["Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Victoria, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Victoria, Australia;","institution_ids":["https://openalex.org/I165779595","https://openalex.org/I2800555584"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"6544","last_page":"6544"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9089999794960022},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.9089999794960022},{"id":"https://openalex.org/keywords/head-and-neck-squamous-cell-carcinoma","display_name":"head and neck squamous cell carcinoma","score":0.9319999814033508},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9020000100135803},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.382999986410141},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.5320000052452087},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-combination-therapy","display_name":"immune checkpoint inhibitor combination","score":0.5740000009536743},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.3310000002384186},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.47699999809265137}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.918030858039856},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6756834983825684},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6269498467445374},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5653931498527527},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43829867243766785},{"id":"https://openalex.org/C2776833033","wikidata":"https://www.wikidata.org/wiki/Q1783924","display_name":"Head and neck squamous-cell carcinoma","level":4,"score":0.414550244808197},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.30730485916137695},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.25928348302841187},{"id":"https://openalex.org/C2776530083","wikidata":"https://www.wikidata.org/wiki/Q1783924","display_name":"Head and neck cancer","level":3,"score":0.24166393280029297},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1966417133808136}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.6544","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.6544","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.6544","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3031455888","https://openalex.org/W4241519036","https://openalex.org/W2978537230","https://openalex.org/W3029297598","https://openalex.org/W4238536342","https://openalex.org/W2741345495","https://openalex.org/W2889599863","https://openalex.org/W2898290601","https://openalex.org/W2756725920","https://openalex.org/W2146819169"],"abstract_inverted_index":{"6544":[0],"Background:":[1],"The":[2,31,340],"KEYNOTE-048":[3],"study":[4,35,231,269],"(Burtness,":[5,144],"at":[6,54,145],"al.":[7,55,76,146],"Lancet":[8,147],"2019;394:1915\u201328)":[9],"led":[10],"to":[11,162,230,268,336,367],"approval":[12],"of":[13,23,57,78,85,104,113,123,210,224,250,343,373],"PE":[14,65,361],"in":[15,46,69,87,178,185,192,310,330,345],"combination":[16,88,346,375],"with":[17,49,64,71,89,347,360],"5-FU/plat":[18,134,180],"for":[19,99,118,141,160,305],"first-line":[20],"(1L)":[21],"treatment":[22,232,270],"head":[24],"and":[25,60,109,189,217,235,257,288,323,358,362,371],"neck":[26],"squamous":[27],"cell":[28],"carcinoma":[29],"(HNSCC).":[30],"Phase":[32],"I":[33],"INDUCE-1":[34],"(NCT02723955)":[36],"has":[37,41,66],"shown":[38],"that":[39,61],"GSK609\u00b1PE":[40,86],"a":[42,102,121],"manageable":[43],"safety":[44,84,94,181,341,370],"profile":[45,342],"patients":[47],"(pts)":[48],"advanced":[50,105],"solid":[51,107],"tumors":[52,108],"(Hansen,":[53],"Annals":[56,77],"Oncology":[58],"2018;29[suppl_8]:viii404)":[59],"GSK609":[62,149,331,337,344],"combined":[63],"anti-tumor":[67],"activity":[68],"pts":[70,175,184,191,200,242,303,314,319,325],"anti-PD-1/L1-na\u00efve":[72],"HNSCC":[73,128],"(Rischin,":[74],"et":[75],"Oncol":[79],"2019;30[Supplement_5]:v454\u20135).":[80],"To":[81],"evaluate":[82],"the":[83,179,186,193,225,262],"5-FU/plat,":[90],"we":[91],"initiated":[92],"additional":[93],"cohorts.":[95],"Methods:":[96],"Pts":[97,116],"eligible":[98,117],"GSK609+5-FU/plat":[100,187],"had":[101,120,315,320],"diagnosis":[103,122],"selected":[106],"\u22645":[110],"prior":[111],"lines":[112],"systemic":[114],"therapy.":[115],"GSK609+PE+5-FU/plat":[119,194],"recurrent":[124],"or":[125,151,166,170,356],"metastatic":[126],"1L":[127],"deemed":[129],"incurable":[130],"by":[131],"local":[132],"therapies.":[133],"was":[135,333],"administered":[136,158],"every":[137],"3":[138,218,226],"weeks":[139],"(Q3W)":[140],"4-6":[142],"cycles":[143,165],"2019;394:1915\u201328);":[148],"24":[150,253],"80":[152],"mg":[153,156],"\u00b1PE":[154],"200":[155],"were":[157,176,214,219,228,254,259,266,299,326,353],"Q3W":[159],"up":[161],"2":[163,313,324,357],"years/35":[164],"until":[167],"disease":[168,322],"progression":[169],"unacceptable":[171],"toxicity.":[172],"Results:":[173],"Twenty-nine":[174],"enrolled":[177],"cohorts:":[182],"10":[183,302],"cohort":[188],"19":[190],"cohort.":[195],"With":[196,238],"GSK609+5-FU/plat,":[197],"9/10":[198],"(90%)":[199],"experienced":[201,243],"\u2265":[202,244],"1":[203,245,355],"adverse":[204],"event":[205],"(AE).":[206],"Of":[207,247,261],"32":[208],"AEs":[209,221,249,298,352],"any":[211,251],"grade,":[212,252],"9":[213],"Grade":[215,255,296],"\u22653":[216,256],"serious":[220],"(SAEs).":[222],"Two":[223],"SAEs":[227],"related":[229,267],"(oral":[233],"mucositis":[234],"febrile":[236],"pancytopenia).":[237],"GSK609+PE+5-FU/plat,":[239],"18/19":[240],"(94.7%)":[241],"AE.":[246],"119":[248],"15":[258,263],"SAEs.":[260],"SAEs,":[264],"11":[265],"(febrile":[271],"neutropenia":[272],"[n=4],":[273],"colitis":[274],"[n=2],":[275],"diarrhea":[276],"[n=1],":[277,279,283],"vomiting":[278],"acute":[280],"kidney":[281],"injury":[282],"cardiac":[284],"chest":[285],"pain":[286],"[n=1]":[287],"lung":[289],"infection":[290],"[n=1]).":[291],"For":[292,301],"all":[293,311],"cohorts,":[294,312],"no":[295],"5":[297],"observed.":[300],"evaluable":[304],"confirmed":[306],"best":[307],"overall":[308],"response":[309],"partial":[316],"response,":[317],"6":[318],"stable":[321],"nonevaluable.":[327],"No":[328],"difference":[329],"exposure":[332],"observed":[334],"relative":[335],"monotherapy.":[338],"Conclusions:":[339],"5-FU/plat\u00b1PE":[348],"is":[349,376],"manageable.":[350],"Most":[351],"Grades":[354],"consistent":[359],"chemotherapy":[363],"toxicities.":[364],"Continued":[365],"follow-up":[366],"investigate":[368],"long-term":[369],"efficacy":[372],"this":[374],"warranted.":[377],"Clinical":[378],"trial":[379],"information:":[380],"NCT02723955":[381],".":[382]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-06-05T00:00:00"}